MX365421B - Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf. - Google Patents

Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.

Info

Publication number
MX365421B
MX365421B MX2015004610A MX2015004610A MX365421B MX 365421 B MX365421 B MX 365421B MX 2015004610 A MX2015004610 A MX 2015004610A MX 2015004610 A MX2015004610 A MX 2015004610A MX 365421 B MX365421 B MX 365421B
Authority
MX
Mexico
Prior art keywords
prostate cancer
maf
prognosis
diagnosis
metastasis
Prior art date
Application number
MX2015004610A
Other languages
English (en)
Other versions
MX2015004610A (es
Inventor
Gomis Roger
Jean-Mairet Joel
Original Assignee
Inbiomotion Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inbiomotion Sl filed Critical Inbiomotion Sl
Publication of MX2015004610A publication Critical patent/MX2015004610A/es
Publication of MX365421B publication Critical patent/MX365421B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

La presente invención se refiera a un método in vitro para el diagnóstico de metástasis en un sujeto con cáncer de próstata y/o para el pronóstico de la tendencia a desarrollar metástasis en un sujeto con cáncer de próstata, el método caracterizado porque comprende; (i) cuantificar el nivel de expresión del gen c-MAF en una muestra de tejido de tumor de próstata del sujeto y (ii) comparar el nivel de expresión obtenido en (i) con el nivel de expresión del gen c-MAF en una muestra de control, en donde si el nivel de expresión del gen c-MAF en la muestra de tejido de tumor se aumenta con respecto al nivel de expresión del gen c-MAF en la muestra de control, entonces el sujeto tiene un diagnóstico positivo para metástasis o una mayor tendencia a desarrollar metástasis.
MX2015004610A 2012-10-12 2013-10-09 Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf. MX365421B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713318P 2012-10-12 2012-10-12
PCT/IB2013/002866 WO2014057357A2 (en) 2012-10-12 2013-10-09 Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Publications (2)

Publication Number Publication Date
MX2015004610A MX2015004610A (es) 2015-10-22
MX365421B true MX365421B (es) 2019-06-03

Family

ID=49998595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004610A MX365421B (es) 2012-10-12 2013-10-09 Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.

Country Status (13)

Country Link
US (4) US20140105918A1 (es)
EP (2) EP2906718B1 (es)
JP (3) JP6074049B2 (es)
KR (1) KR101872965B1 (es)
CN (1) CN104995313A (es)
AU (1) AU2016213773B2 (es)
BR (1) BR112015008255B1 (es)
CA (1) CA2888122A1 (es)
DK (1) DK2906718T3 (es)
ES (2) ES2744244T3 (es)
HK (1) HK1213946A1 (es)
MX (1) MX365421B (es)
WO (1) WO2014057357A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102240323B1 (ko) 2010-10-06 2021-04-14 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) 유방암 전이의 진단, 예후 및 치료 방법
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
DK2859120T3 (en) 2012-06-06 2019-01-14 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for diagnosis and prognosis of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CN104995313A (zh) * 2012-10-12 2015-10-21 生物运动有限公司 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法
US20160032399A1 (en) * 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
WO2014140896A2 (es) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
US11206976B2 (en) * 2014-10-16 2021-12-28 New York University Method and system for simultaneous decomposition of multiple hyperspectral datasets and signal recovery of unknown fluorophores in a biochemical system
JP2017538412A (ja) * 2014-12-11 2017-12-28 インバイオモーション エセ．エレ． ヒトｃ−ｍａｆに対する結合メンバー
WO2016209926A1 (en) * 2015-06-22 2016-12-29 Thomas Jefferson University Cancers expressing ccr5 and methods of treatment of same
KR102571924B1 (ko) * 2016-05-25 2023-08-28 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
CZ2016821A3 (cs) * 2016-12-22 2018-07-04 České vysoké učení technické v Praze Kombinace pro radionuklidovou terapii pro použití jako léčivo
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
TW202012637A (zh) * 2018-04-24 2020-04-01 瑞典商阿斯特捷利康公司 治療癌症之方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986004920A1 (en) 1985-02-13 1986-08-28 Biotechnology Research Partners, Limited Human metallothionein-ii promoter in mammalian expression system
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
CA2251466A1 (en) 1996-04-05 1997-10-16 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US6355623B2 (en) 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
PL350456A1 (en) 1999-03-15 2002-12-16 Axys Pharmaceuticals N−cyanomethylamides as protease inhibitors
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
AU779855B2 (en) 2000-01-06 2005-02-17 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
US6774131B1 (en) 2000-02-16 2004-08-10 Yamanouchi Pharmaceutical Co., Ltd. Remedies for endothelin-induced diseases
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
JP4579581B2 (ja) 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のｈｌａ−ａ２４またはｈｌａ−ａ２結合ペプチド
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
JP2007524671A (ja) * 2004-01-21 2007-08-30 カイロン コーポレイション Ｍ−ｃｓｆムテインおよびその使用
CA2567942A1 (en) 2004-05-26 2005-12-08 Green Peptide Co., Ltd. Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
WO2007053245A2 (en) 2005-09-20 2007-05-10 Immunivest Corporation Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
CA2632451C (en) 2005-12-06 2015-11-03 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP5142288B2 (ja) * 2006-04-05 2013-02-13 公立大学法人横浜市立大学 前立腺癌の予後判定方法及びそのための診断薬
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2211861A4 (en) 2007-10-18 2010-08-25 Univ Health Network CLIOQUINOL IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
WO2009146546A1 (en) 2008-06-06 2009-12-10 University Health Network 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
AR075613A1 (es) 2009-02-25 2011-04-20 Merrion Res Iii Ltd Composicion y suministro de drogas de bifosfonato. metodo de tratamiento
ES2379918B1 (es) 2010-10-06 2013-05-10 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
KR102240323B1 (ko) * 2010-10-06 2021-04-14 펀다시오 인스티튜트 드 르세르카 바이오메디카(아이알비 바르셀로나) 유방암 전이의 진단, 예후 및 치료 방법
EP2671076A4 (en) 2011-02-04 2016-11-16 Bioarray Genetics Inc METHODS OF USING GENE EXPRESSION SIGNATURES FOR SELECTING A TREATMENT METHOD, PREDICTING PROGNOSIS, SURVIVAL, AND / OR PREDICTING A RESPONSE TO TREATMENT
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
DK2859120T3 (en) 2012-06-06 2019-01-14 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for diagnosis and prognosis of lung cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CN104995313A (zh) * 2012-10-12 2015-10-21 生物运动有限公司 使用c-maf的前列腺癌转移的诊断、预后和治疗的方法
US20160032400A1 (en) 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
WO2014140896A2 (es) 2013-03-15 2014-09-18 Fundacio Privada Institut De Recerca Biomedica Metodo para el diagnostico, pronostico y tratamiento de la metastasis de un cancer
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
DK3158057T3 (da) 2014-06-17 2019-07-29 Igenomix S L Stamcelleterapi ved endometriepatologier
JP2017538412A (ja) 2014-12-11 2017-12-28 インバイオモーション エセ．エレ． ヒトｃ−ｍａｆに対する結合メンバー
KR102571924B1 (ko) 2016-05-25 2023-08-28 인바이오모션 에스.엘. c-MAF 상태에 기초한 유방암의 치료
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료

Also Published As

Publication number Publication date
JP6446381B2 (ja) 2018-12-26
US20190242898A1 (en) 2019-08-08
AU2016213773A1 (en) 2016-09-01
AU2013328385A1 (en) 2015-05-07
HK1213946A1 (zh) 2016-07-15
CN104995313A (zh) 2015-10-21
US20220042997A1 (en) 2022-02-10
JP6636067B2 (ja) 2020-01-29
EP3553186A1 (en) 2019-10-16
JP2018078911A (ja) 2018-05-24
US10114022B2 (en) 2018-10-30
CA2888122A1 (en) 2014-04-17
US11892453B2 (en) 2024-02-06
MX2015004610A (es) 2015-10-22
WO2014057357A3 (en) 2014-05-30
EP3553186B1 (en) 2021-11-17
US20140105918A1 (en) 2014-04-17
EP2906718B1 (en) 2019-05-15
JP6074049B2 (ja) 2017-02-01
BR112015008255B1 (pt) 2023-02-28
AU2016213773B2 (en) 2018-06-07
KR101872965B1 (ko) 2018-06-29
JP2016500517A (ja) 2016-01-14
US11041861B2 (en) 2021-06-22
JP2016105731A (ja) 2016-06-16
US20150362495A1 (en) 2015-12-17
KR20150105297A (ko) 2015-09-16
EP2906718A2 (en) 2015-08-19
DK2906718T3 (da) 2019-07-01
BR112015008255A2 (pt) 2017-11-28
WO2014057357A2 (en) 2014-04-17
ES2906586T3 (es) 2022-04-19
ES2744244T3 (es) 2020-02-24

Similar Documents

Publication Publication Date Title
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2013003880A (es) Metodo para diagnostico, pronostico y tratamiento de la metastasis de carcer de mama.
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
EA201290901A1 (ru) Фитоканнабиноиды для лечения злокачественной опухоли
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
MY182773A (en) Method for indicating a presence or non-presence of aggressive prostate cancer
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
EA201590747A1 (ru) Способы лечения с использованием аденовируса
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
MX2013005507A (es) Metodos para tratamiento de tumores.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
MX343803B (es) Complejo de ipp como marcador para tratamiento de erlotinib.
WO2013188823A3 (en) Cancer prognostic assays

Legal Events

Date Code Title Description
FG Grant or registration